Search Results for "RNAi"
Alnylam is committed to providing the healthcare community with balanced, accurate, and high-quality information about our science, therapeutic areas, and products.
More than one search term is recommended to yield the most relevant results. By searching, you confirm that your query is unsolicited.
For more information about our FDA-approved therapies, please see the Full Prescribing Information:
RNAi Data Navigator: Focus on Vutrisiran
This interactive PDF provides an overview of ATTR-CM and RNAi therapeutics, and offers a deep dive into the vutrisiran data in ATTR-CM from the HELIOS-B trial, including the primary and additional analyses. Alnylam's ongoing commitment to ATTR amyloidosis is reflected in a summary of the current pipeline and TRITON-CM study design.
This interactive PDF provides an overview of ATTR-CM and RNAi therapeutics, and offers a deep dive into the vutrisiran data in ATTR-CM from the HELIOS-B trial, including the primary and additional analyses. Alnylam's ongoing commitment to ATTR amyloidosis is reflected in a summary of the current pipeline and TRITON-CM study design.
Patisiran: Hospitalization and Mortality
Standard response letter on hospitalization and mortality data from patisiran clinical trials.
Standard response letter on hospitalization and mortality data from patisiran clinical trials.
Zilebesiran: KARDIA-2 Study
Standard response letter on zilebesiran and the KARDIA-2 study, a phase 2 study evaluating the efficacy and safety of zilebesiran as add-on therapy in patients with hypertension not adequately controlled by a standard-of-care antihypertensive medication including diuretic (indapamide), CCB (amlodipine), or ARB (olmesartan).
Standard response letter on zilebesiran and the KARDIA-2 study, a phase 2 study evaluating the efficacy and safety of zilebesiran as add-on therapy in patients with hypertension not adequately controlled by a standard-of-care antihypertensive medication including diuretic (indapamide), CCB (amlodipine), or ARB (olmesartan).
Lumasiran Clinical Program Overview
This infographic details the lumasiran clinical program (including ILLUMINATE) which investigates the treatment of primary hyperoxaluria type 1 with lumasiran.
This infographic details the lumasiran clinical program (including ILLUMINATE) which investigates the treatment of primary hyperoxaluria type 1 with lumasiran.
Patisiran RWE in hATTR Amyloidosis
External title: Patisiran RWE in hATTR Amyloidosis
External description: This slide deck highlights real-world evidence (RWE) data on the use of patisiran in patients with hATTR amyloidosis, including patients with polyneuropathy, cardiomyopathy, solid organ transplant, concomitant treatment or treatment switch.
External title: Patisiran RWE in hATTR Amyloidosis External description: This slide deck highlights real-world evidence (RWE) data on the use of patisiran in patients with hATTR amyloidosis, including patients with polyneuropathy, cardiomyopathy, solid organ transplant, concomitant treatment or treatment switch.
